APRE Projected Dividend Yield

Aprea Therapeutics Inc ( NASDAQ : APRE )

Aprea Therapeutics is a clinical-stage biopharmaceutical company. Co.'s primary synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR), a kinase that plays a critical role in DNA damage response (DDR). Co. is targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Co.'s primary WEE1 inhibitor product candidate is ATRN-1051. In addition, Co. has a preclinical research program directed at a second-generation ATR inhibitor, ATRN-354. Finally, Co. also has an early preclinical research program, which is aimed at identification of inhibitors of a distinct protein involved in DDR.

20 YEAR PERFORMANCE RESULTS